Big cannabis companies win biggest—rescheduling unlocks banking, taxes, and scale that crushes mom-and-pops while patients see little change.
Spot on, but don't forget the Big Pharma crossover. Schedule III brings strict FDA oversight, and only massive corporations have the capital to survive those compliance costs.
